VGA039

DRUG3 trials

Sponsors

Vega Therapeutics Inc., Vega Therapeutics, Inc

Conditions

Von Willebrand Disease (VWD)Von Willebrand Diseasesvon Willebrand Disease

Phase 1

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

RecruitingNCT05776069

Vega Therapeutics, IncVon Willebrand Diseases

Start: 2023-03-16End: 2029-12-31Target: 116Updated: 2025-08-26

Phase 3

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

RecruitingNCT07115004

Vega Therapeutics, IncVon Willebrand Disease (VWD)

Start: 2025-10-15End: 2028-10-01Target: 60Updated: 2026-09-14

A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients with von Willebrand Disease (VIVID-6)

Not yet recruitingCTIS2025-522056-10-01

Vega Therapeutics Inc.von Willebrand Disease

Target: 14Updated: 2026-01-26

Related Papers

Subcutaneous, every-four-week maintenance dosing of a novel protein S antibody is well-tolerated and substantially reduces bleeding rates: Results from A phase 1/2 multidose study of VGA039 in patients with von Willebrand disease

Blood2025-11-03

VGA039 as a protein S-targeted hemostatic promoting monoclonal antibody, promotes in-vitro thrombin generation in plasma samples from subjects across a broad range of bleeding disorders, including von Willebrand disease, hemophilia A, hemophilia B and hemophilia C

Blood2025-11-03

A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding

Blood2024-11-054 citations